Scarica l'app Stockscreener
3.51
0.85%
-0.03
Precedente Chiudi:
$3.54
Aprire:
$3.49
Volume 24 ore:
94,901
Relative Volume:
0.64
Capitalizzazione di mercato:
$165.66M
Reddito:
$7.15M
Utile/perdita netta:
$-20.60M
Rapporto P/E:
7.3957
EPS:
0.4746
Flusso di cassa netto:
$-97.99M
1 W Prestazione:
-1.68%
1M Prestazione:
+8.33%
6M Prestazione:
+80.93%
1 anno Prestazione:
+106.47%
Intervallo 1D:
$3.395
$3.595
Intervallo di 1 settimana:
$3.15
$3.805
Portata 52W:
$1.39
$4.4799
Whitehawk Therapeutics Inc Stock (WHWK) Company Profile
Nome
Whitehawk Therapeutics Inc
Settore
Industria
Telefono
551-321-2234
Indirizzo
2 HEADQUARTERS PLAZA, MORRISTOWN
Compare WHWK vs VRTX, REGN, ARGX, ALNY, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
WHWK
Whitehawk Therapeutics Inc
|
3.51 | 165.66M | 7.15M | -20.60M | -97.99M | 0.4746 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Whitehawk Therapeutics Inc Stock (WHWK) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-05 | Iniziato | Oppenheimer | Outperform |
| 2024-08-27 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2024-08-21 | Downgrade | Jefferies | Buy → Hold |
| 2024-08-21 | Downgrade | TD Cowen | Buy → Hold |
| 2023-12-15 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2022-01-11 | Iniziato | Jefferies | Buy |
| 2021-10-01 | Iniziato | Cowen | Outperform |
| 2021-09-14 | Iniziato | Ladenburg Thalmann | Buy |
| 2021-09-08 | Iniziato | Piper Sandler | Overweight |
Mostra tutto
Whitehawk Therapeutics Inc Borsa (WHWK) Ultime notizie
Volume Recap: Does Whitehawk Therapeutics Inc have a sustainable dividendQuarterly Growth Report & Verified Short-Term Plans - baoquankhu1.vn
Whitehawk therapeutics CEO Lennon sells $93k in shares By Investing.com - Investing.com South Africa
Whitehawk therapeutics CEO Lennon sells $93k in shares - Investing.com
WHWK: Whitehawk Therapeutics, Inc.Comparative Chart - Zacks Investment Research
Gap Down: Will Whitehawk Therapeutics Inc outperform the market in YEAR2026 Levels & Risk Controlled Swing Alerts - baoquankhu1.vn
Portfolio Update: Does Whitehawk Therapeutics Inc have a sustainable dividendWall Street Watch & Safe Entry Trade Signal Reports - baoquankhu1.vn
Whitehawk Therapeutics (WHWK) price target increased by 13.33% to 5.78 - MSN
Whitehawk’s First-in-Human PTK7 ADC Trial Moves Ahead: What Investors Should Know - TipRanks
Nasdaq Moves: Can Whitehawk Therapeutics Inc reach resistance levels soon2026 Buyback Activity & Risk Controlled Daily Plans - baoquankhu1.vn
Aug Selloffs: Can Whitehawk Therapeutics Inc reach resistance levels soon2026 Intraday Action & Technical Buy Zone Confirmation - baoquankhu1.vn
Bank Watch: What are Whitehawk Therapeutics Incs earnings expectationsVolume Spike & Free Safe Entry Trade Signal Reports - baoquankhu1.vn
Meme Stocks: Will Whitehawk Therapeutics Inc benefit from government policyWeekly Trading Summary & Intraday High Probability Setup Alerts - baoquankhu1.vn
Wall Street Zen Upgrades Whitehawk Therapeutics (NASDAQ:WHWK) to Hold - MarketBeat
Whitehawk Therapeutics, Inc.: Fundamental Analysis and Financial Ratings | 3350 | US00032Q1040 - marketscreener.com
Aug Technicals: Can Whitehawk Therapeutics Inc sustain its profitability2026 Biggest Moves & Entry Point Confirmation Signals - baoquankhu1.vn
Pullback Watch: Does Whitehawk Therapeutics Inc have a sustainable dividendWeekly Stock Summary & Accurate Trade Setup Notifications - baoquankhu1.vn
Whitehawk Therapeutics to Highlight its Next-Generation ADC Portfolio at the American Association for Cancer Research (AACR) Annual Meeting 2026 - PR Newswire
Whitehawk Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Aug Patterns: How does Whitehawk Therapeutics Inc score in quality rankingsMarket Sentiment Report & Real-Time Market Trend Scan - baoquankhu1.vn
Whitehawk Therapeutics Inc PE Ratio (TTM) & PE Ratio (TTM) ChartsWHWK - GuruFocus
Oppenheimer Sticks to Their Buy Rating for Whitehawk Therapeutics (WHWK) - The Globe and Mail
Suvretta Capital Management LLC Buys Shares of 3,700,000 Whitehawk Therapeutics, Inc. $WHWK - MarketBeat
2,849,402 Shares in Whitehawk Therapeutics, Inc. $WHWK Purchased by Avoro Capital Advisors LLC - MarketBeat
Whitehawk Therapeutics (WHWK) Swings To US$0.37 EPS Profit Challenging Bearish Turnaround Skepticism - simplywall.st
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Rapid Micro Biosystems (RPID), Lexicon Pharmaceuticals (LXRX) and Whitehawk Therapeutics (WHWK) - The Globe and Mail
Whitehawk Therapeutics Inc expected to post a loss of 6 cents a shareEarnings Preview - TradingView
Whitehawk Therapeutics 2025 10-K Overview: Next-Generation ADC Cancer Therapies, Pipeline, and Strategic Partnerships - Minichart
WHITEHAWK THERAPEUTICS ($WHWK) Releases Q4 2025 Earnings - Quiver Quantitative
Whitehawk Therapeutics Q4 EPS $(0.34) Misses $(0.13) EstimateWhitehawk Therapeutics (NASDAQ:WHWK) - Benzinga
Whitehawk Therapeutics reports bigger-than-expected Q4 loss on higher R&D costs - TradingView
Whitehawk Therapeutics (WHWK) boosts 2025 cash to $145.7M and advances ADC pipeline - Stock Titan
Whitehawk Therapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Highlights - PR Newswire
Whitehawk Therapeutics (WHWK) price target increased by 11.11% to 5.10 - MSN
David James Lennon Sells 5,100 Shares of Whitehawk Therapeutics (NASDAQ:WHWK) Stock - MarketBeat
Whitehawk Therapeutics (WHWK) CEO sells shares to cover RSU tax - Stock Titan
Whitehawk Therapeutics (WHWK) CFO sells shares to cover tax bill - Stock Titan
Aadi Bioscience Conference: Whitehawk Unveils 3-Program ADC Pipeline, Targets First Data in 2027 - MarketBeat
Jones Trading initiates coverage of Whitehawk Therapeutics (WHWK) with buy recommendation - MSN
Why Whitehawk Therapeutics Inc. stock is a value investor pickEarnings Beat & Verified Chart Pattern Trade Signals - Naître et grandir
Insider Trends: What are the risks of holding Whitehawk Therapeutics IncWeekly Risk Summary & AI Powered Trade Plan Recommendations - baoquankhu1.vn
Can Whitehawk Therapeutics Inc reach resistance levels soon2025 Market Trends & Low Risk Entry Point Guides - baoquankhu1.vn
Aadi Bioscience Conference: Whitehawk CEO Details 3-Program ADC Pipeline, First Data Seen in 2027 - Defense World
Aug Closing: Can Whitehawk Therapeutics Inc reach resistance levels soonJuly 2025 Short Interest & Free Expert Verified Stock Movement Alerts - baoquankhu1.vn
Whitehawk Therapeutics : Corporate Presentation March 2026 - marketscreener.com
WHWK: Three differentiated ADCs in parallel, targeting broad cancers with best-in-class stability and safety - TradingView
Whitehawk Therapeutics to Participate in Upcoming Investor Conferences - PR Newswire
Whitehawk Therapeutics (WHWK) Price Target Increased by 11.11% to 5.10 - Nasdaq
Aadi Bioscience Conference: CEO Spotlights Whitehawk ADC Pipeline, Cash Runway Through 2028 - Yahoo Finance
WHWK Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
WHWKWhitehawk Therapeutics Inc Latest Stock News & Market Updates - Stock Titan
Whitehawk Therapeutics Inc Azioni (WHWK) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):